In order to assess the efficacy of adjuvant radiotherapy in the treatment of pathological stage I endometrial carcinoma, we performed a retrospective analysis of 158 patients with this diagnosis who after surgery were either treated with radiation therapy or only followed from January 1980 through December 1987.
Methods
Patients were divided into two prognostic categories, high and low risk, on the basis of three known predictors of survival: histology, differentiation, and depth of myometrial invasion. All patients underwent total abdominal hysterectomy and bilateral salpingooophorectomy but only the high risk group received radiotherapy as well.
Results
After a median follow up time of 59 months the survival rates of the two groups were similar. The 5-year disease-free survival of the surgery alone group was 92 % compared to 89 % for the postoperative radiotherapy group. Side effects of treatment were minimal.
Conclusions
Postoperative radiation therapy for high risk pathological stage I endometrial carcinoma is an effective adjuvant therapy and confers an excellent prognosis.
AaldersJ., AbelerV., KolstadP., OnsrudM.: Postoperative external irradiation and prognostic parameters in stage I endometrial carcinoma: Clinical and histophathologic study of 540 patients. Obstet. Gynecol., 56: 419–427, 1980.
2.
ChungC., StrykerW., NahhasW., MortelR.: The role of adjunctive radiotherapy for stage I endometrial carcinoma: Preoperative versus postoperative irradiation. Int. J. Radiat. Oncol. Biol. Phys., 7: 1429–1435, 1981.
3.
Classification and staging of malignant tumors in the female pelvis (accepted by the general assembly of FIGO in New York, 12 April 1970). Acta. Obstet. Gynecol. Scand., 50: 1–7, 1971.
4.
CohenY., MohileverY.: An interactive report generator for clinical and radiation oncology. In: Computers in Radiology and Oncology.HilgerA. (Ed.), Bristol, 207–212, 1984.
5.
CreasmanW.T., DiSaiaP.J., BlessingJ., WilkinsonR.H., JohnstonW., WeedJ.C.: Prognostic significance of peritoneal cytology in patients with endometrial cancer and preliminary data concerning therapy with intraperitoneal radiopharmaceuticals. Am. J. Obstet. Gynecol., 141: 921–929, 1981.
6.
EifelP., RossJ., HendricksonM., CoxR.S., KempsonR., MartinezA.: Adenocarcinoma of the endometrium: Analysis of 256 cases with disease limited to the uterine corpus: treatment comparisons. Cancer, 52: 1026–1031, 1983.
7.
FayosJ., MoralesP.: Carcinoma of the endometrium. Results of treatment. Int. J. Radiat. Oncol., Biol. Phys., 6: 571–576, 1980.
8.
GibbonsS., MartinezM., SchrayM., PodratzK., StanhopeR., GartonG., WeinerS., BrabbinsD., MalkasianG.: Adjuvant whole abdominopelvic irradiation for high risk endometrial carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 21: 1019–1025, 1991.
9.
GrigsbyP.W., PerezC.A., KutenA.: Clinical stage I endometrial cancer: Results of adjuvant irradiation and patterns of failure. Int. J. Radiat. Oncol. Biol. Phys., 21: 379–385, 1991.
10.
HendricksonM., RossJ., EifelP., MartinezA., KempsonR.: Uterine papillary serous carcinoma: A highly malignant form of endometrial adenocarcinoma. Am. J. Surg. Pathol., 6: 93–100, 1982.
11.
HomeslyH.D., BoronowR.C., LewisJ.L.: Treatment of adenocarcinoma of the endometrium at Memorial-James Ewing Hospitals. 1949-1965. Obstet. Gynecol., 47: 100–105, 1976.
12.
International Commission on Radiation Units and Measurement (ICRU).Dose and volume specification for reporting intracavitary therapy in gynecology. ICRU Report 38. Bethesda, Maryland, USA.
13.
KaplanE., MeierP.: Non-parametric estimation from incomplete observation. J. Am. Stat. Assoc., 53: 457–481, 1958.
14.
MalkasianG.D.: Carcinoma of the endometrium: Effects of stage and grade on survival. Cancer, 41: 996–1001, 1978.
15.
MalkasianG., AnnegeresJ., FountainK.: Carcinoma of the endometrium: Stage I. Am. J. Obstet. Gynecol., 138: 872–888, 1980.
16.
MalkasianG.D., McDonaldI.W., PrattJ.H.: Carcinoma of the endometrium. Mayo Clinic experience. Mayo Clin. Proc52: 175–180, 1977.
17.
NahhasW., LundC., RudolphJ.: Carcinoma of the corpus uteri: A 10 year review of 225 patients. Obstet. Gynecol38: 564–569, 1971.
18.
SalazarD., FeldsteinM., DePappE., BonfiglioT., KellerB., RubinP., RudolphJ.: The management of clinical stage I endometrial carcinoma. Cancer, 41: 1016–1026, 1978.
19.
SallS., SonnenblickB., StoneM.L.: Factors affecting survival of patients with endometrial adenocarcinoma. Am. J. Obstet. Gynecol., 107: 116–123, 1970.
20.
SauseW.T., FullerD.B., SmithW.G., JohnsonG.H., PlenkH.P., MenloveR.L.: Analysis of preoperative intracavitary cesium application in high risk stage I endometrial carcinoma. Int. J. Radiat. Oncol. Biol. Phys., 15 (suppl.): 141, 1988.
21.
SharmaS.C., GerbiB., Medoc-JonesH.: Dose rate for brachytherapy applicators using 137 Cs sources. Int. J. Radiat. Oncol. Biol. Phys., 5: 1893–1897, 1979.
22.
SilverbergE.: Cancer statistics. CA, 32: 15–31, 1982.
23.
StokesS., BedwinekJ., KaoM.S., CamelH.M., PerezC.A.: Treatment of stage I adenocarcinoma of the endometrium by hysterectomy and adjuvant irradiation: A retrospective analysis of 304 patients. Int. J. Radiat. Oncol. Biol. Phys., 12: 339–344, 1986.
24.
ShimD.S., WangC.C., FullerA.F., NelsonJ.H., NikruiN., YoungR.H., ScullyR.E.: Management of high grade stage I adenocarcinoma of the endometrium: Hysterectomy following low dose external beam pelvis irradiation. Gynecol. Oncol., 23: 183–191, 1986.
UnderwoodP.B., LutzM.H., KreutnerA., MillerM.C., JohnsonR.B.: Carcinoma of the endometrium- radiation followed immediately by operation. Am. J. Obstet. Gynecol., 128: 86–98, 1977.
27.
WelanderC., GriemM.L., NewtonM.: Staging and treatment of endometrial carcinoma. J. Reprod. Med., 8: 41–46, 1972.
